🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

63 results for “Merck KGaA, Darmstadt, Germany” Clear

  1. Clesrovimab

    Merck KGaA, Darmstadt, Germany

    Respiratory Syncytial Virus Infection

    phase 3 mab completed

    1 trial

  2. DOR/ISL

    Merck KGaA, Darmstadt, Germany

    HIV Infection

    phase 3 small molecule active

    1 trial

  3. IV Tulisokibart

    Merck KGaA, Darmstadt, Germany

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  4. IV Tulisokibart

    Merck KGaA, Darmstadt, Germany

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  5. Lenvatinib

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Hepatocellular

    phase 3 small molecule completed

    1 trial

  6. MK-8527

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV)

    phase 3 small molecule active

    1 trial

  7. Molnupiravir

    Merck KGaA, Darmstadt, Germany

    Coronavirus Disease (COVID-19)

    phase 3 small molecule active

    2 trials

  8. Nemtabrutinib

    Merck KGaA, Darmstadt, Germany

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  9. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Metastatic Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  10. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Ovarian Cancer

    phase 3 mab completed

    1 trial

  11. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Urinary Bladder Neoplasms

    phase 3 small molecule active

    1 trial

  12. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Renal Cell Carcinoma

    phase 3 mab completed

    1 trial

  13. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Renal Cell

    phase 3 mab active

    1 trial

  14. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Cervical Cancer

    phase 3 mab completed

    1 trial

  15. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 3 small molecule active

    1 trial

  16. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Triple Negative Breast Neoplasms

    phase 3 mab completed

    1 trial

  17. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Endometrial Neoplasms

    phase 3 mab active

    1 trial

  18. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Gastric Neoplasms

    phase 3 mab completed

    1 trial

  19. Pembrolizumab (K)

    Merck KGaA, Darmstadt, Germany

    Breast Cancer

    phase 3 mab active

    1 trial

  20. Pembrolizumab/Vibostolimab

    Merck KGaA, Darmstadt, Germany

    Lung Neoplasms

    phase 3 mab completed

    1 trial

  21. Prevnar 13™

    Merck KGaA, Darmstadt, Germany

    Pneumococcal Infections

    phase 3 mab completed

    1 trial

  22. Recombinant human luteinizing hormone (r-hLH)

    Merck KGaA, Darmstadt, Germany

    Hypogonadism

    phase 3 small molecule completed

    1 trial

  23. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  24. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer

    phase 3 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources